Table 4 Targeting cell death pathways for cancer therapy
Drugs | Title | Pathways | Cancer | Death |
|---|---|---|---|---|
FL118 | Pyroptosis is involved in the inhibitory effect of FL118 on growth and metastasis in colorectal cancer | NLRP3-ASC-Caspase-1 | Colorectal cancer | Pyroptosis |
Simvastatin | Simvastatin Suppresses Proliferation and Migration in Non-small Cell Lung Cancer via Pyroptosis | NLRP3-caspase-1-IL-1β and IL-18 | Non-small cell lung cancer | Pyroptosis |
Nanotoxin | A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy | CXCR4-caspase-3-GSDME | Melanoma | Pyroptosis |
Erastin | Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma | FOXM1-Nedd4-VDAC2/3 | Melanoma | Ferroptosis |
Erastin | CAF secreted miR−522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer | Exo-miR−522 and ALOX15 | Gastric cancer | Ferroptosis |
Erastin | Deubiquitinase USP35 modulates ferroptosis in lung cancer via targeting ferroportin | USP35-FPN | Lung cancer | Ferroptosis |
Sorafenib and erastin | Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer | FDX1-GSH | Liver cancer | Ferroptosis |
Sulfasalazine | CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer | CISD2 -lipid ROS | Neck cancer | Ferroptosis |
Sorafenib | Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer | ATF2-HSPH1-SL7A11 | Gastric cancer | Ferroptosis |
Bortezomib | The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma | IGFBP2 | Glioma | Cuproptosis |
Trientine tetrahydrochloride, penicillamine | Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial | Inhibitors of acetyltransferases, copper ion concentration | Wilson disease | Cuproptosis |
Triethylenetetramine (trientine) | Triethylenetetramine (trientine): a caloric restriction mimetic with a new mode of action | Inhibitors of acetyltransferases, copper ion concentration | Wilson disease | Cuproptosis |
GOx@[Cu(tz)] | An Enzyme-Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis-Based Synergistic Cancer Therapy | SAT1-AcCoA | Bladder cancer | Cuproptosis |